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POLIMORFISMA GENETIK BAGI GEN REAKSI KERADANGAN DAN 
PENGARUHNYA TERHADAP PESAKIT BARAH KOLOREKTAL DI 
MALAYSIA- SATU KAJIAN KES KAWALAN 
 
ABSTRAK 
 
Barah kolorektal (CRC) secara rawak adalah penyakit yang kompleks dan 
disebabkan oleh pelbagai faktor seperti interaksi faktor-faktor alam sekitar dan 
kecenderungan genetik. Walau bagaimanapun, kecenderungan genetik atau risiko 
kecenderungan individu tertentu untuk  menghidap CRC  masih tidak dapat 
ditentukan. Kebelakangan ini keradangan kronik telah dilaporkan  sebagai faktor 
kecenderungan untuk menghidapi CRC. Hipotesis menunjukkan bahawa profil 
genetik pro-radang yang diwakili oleh perubahan genetik di dalam gen-gen tindak 
balas keradangan mungkin mempunyai kaitan dengan kecenderungan kepada CRC 
yang semakin meningkat dan satu kajian telah direka untuk menguji hipotesis ini. 
Enam polimorfisma daripada lima gen yang terlibat dalam tindak balas keradangan 
seperti IL-8 -251 T> A, TNF-α -308 G> A, ICAM-1 K469E, ICAM-1 R241G, IL-6 -
174 G> C, dan PPAR-γ 34 C> G telah dipilih sebagai calon (Polimorfisma 
Nukleotida Tunggal) SNPs untuk mengenalpasti sejauh mana pengaruh mereka, 
sama ada secara tunggal atau kombinasi untuk bertindak sebagai pengantara terhadap 
risiko kecenderungan menghidap CRC dengan matlamat akhir untuk mengenal pasti 
risiko dan / atau genotip perlindungan. Kajian kes-kawalan ini, melibatkan 510 
subjek kajian dengan 255 pesakit disahkan disahkan secara histopatologi sebagai 
pesakit CRC dan 255 individu biasa yang sihat sebagai kawalan. Setelah mendapat 
persetujuan secara bertulis, sampel darah periferi untuk semua subjek kajian 
xxiii 
 
dikumpulkan, DNA genomik diekstrak dan digenotip menggunakan PCR-RFLP dan 
Alel Khusus PCR, diikuti oleh analisis penjujukan DNA. Genotip dikategorikan 
kepada jenis homozigus normal, heterozigus variasi dan homozigus variasi. 
Frekuensi genotip dan kaitan risiko kepada penyakit telah dianalisis menggunakan 
pakej statistik. Kekuatan kaitannya dengan antara genotip polimorfik dan 
kecenderungan risiko barah kolorektal telah dinilai dengan merujuk kepada ‘Odds 
Ratio’ (OR) dengan mewakili 95 %CI menggunakan regresi logistik tanpa syarat. 
Untuk membandingkan frekuensi genotip bagi semua SNPs pesakit dan kawalan, 
genotip homozygus variasi IL-8 -251 AA dan TNF-α -308 AA dan alel jauh lebih 
tinggi di kalangan pesakit CRC. Kajian ke atas kaitan alel varian dan genotip secara 
tunggal, dengan risiko kecenderungan menunjukkan alel homozigus variasi dan 
genotip IL-8 -251 AA dan TNF-α -308 AA pada risiko yang lebih tinggi untuk 
kecenderungan pada CRC. Apabila dianalisis dalam 2 cara gabungan genotip, IL-8 -
251AA/ICAM-1 R241R, IL-8-251AA / IL-6-174GG, IL-8-251AA / PPAR-γ 34CC, 
TNF-α-308AA / ICAM-1 R241R, TNF-α -308 GA / IL-6-174GG dan TNF-α -
308AA/IL-6-174GG telah muncul sebagai genotip kombinasi kecenderungan risiko 
yang tinggi. Hasil kajian ini menunjukkan ada kebarangkalian bahawa SNPs 
menunjukkan risiko yang lebih tinggi mungkin menggalakkan kecenderungan CRC 
dengan mengubah sifat-sifat ‘cytokine’ dan ‘chemokine’ dan bertindak sebagai 
pengawal negatif bagi pertumbuhan sel. Adalah munasabah untuk membuat 
kesimpulan bahawa dalam keadaan keradangan yang berterusan, perubahan genetik 
(SNPs) di dalam gen-gen yang bertindak di dalam tindak balas imun dan keradangan, 
yang boleh mengakibatkan tindak balas yang menyimpang sistem imun perumah, 
boleh bertindak sebagai faktor-faktor kecenderungan genetik, yang memihak kepada 
karsinogenesis kolorektal yang diperantarai oleh keradangan.  
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GENETIC POLYMORPHISMS OF INFLAMMATION RESPONSE GENES 
AND THEIR INFLUENCE ON MALAYSIAN COLORECTAL CANCER 
PATIENTS- A CASE CONTROL STUDY 
 
ABSTRACT 
  
Sporadic colorectal cancer (CRC) is a complex and multi-factorial disease caused by 
the interaction of environmental and genetic predisposition factors. However the 
genetic susceptibility or predisposition risk of a certain individual to development of 
sporadic CRC remains largely undetermined. Recently chronic inflammation has 
been documented as a predisposing factor for CRC development. It was 
hypothesized that a pro-inflammatory genetic profile represented by genetic variation 
in inflammation response genes might be associated with increased susceptibility to 
CRC and a study was designed to test the hypothesis. Six polymorphisms of five 
genes involved in inflammation response such as IL-8 -251 T>A, TNF-α -308 G>A, 
ICAM-1 K469E, ICAM-1 R241G, IL-6 -174 G>C, and PPAR-γ 34 C>G were 
selected as candidate SNPs (Single Nucleotide Polymorphisms) to determine their 
influence, either singly or in combinations in mediating CRC susceptibility risk, with 
the final aim of identifying the at risk and/or protective genotypes. This case-control 
study, involved 510 study subjects with 255 histopathologically confirmed CRC 
patients as cases and 255 healthy normal individuals as controls. After getting 
informed consent, peripheral blood samples of all study subjects were collected, 
genomic DNA was extracted and genotyped employing Polymerase Chain Reaction-
Restriction Fragment Length Polymorphism (PCR-RFLP) and Allele Specific PCR, 
followed by sequencing. Genotypes were categorized into homozygous wild type, 
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heterozygous and homozygous variants. Genotype frequencies and their risk 
associations were analyzed using statistical methods. The strength of association 
between polymorphic genotypes and colorectal cancer susceptibility risk was 
assessed by deriving Odds Ratio (OR) with corresponding 95 % CI using 
unconditional logistic regression. On comparing the frequencies of genotypes of all 
SNPs in patients and controls, the homozygous variant genotypes IL-8 -251 AA and 
TNF-α -308 AA and alleles were significantly higher in CRC patients. Investigation 
on the association of the variant alleles and genotypes singly, with susceptibility risk 
showed the homozygous variant alleles and genotypes IL-8 -251 AA and TNF-α -308 
AA at higher risk for CRC predisposition. When analyzed in 2 way genotype 
combinations, IL-8 -251AA/ICAM-1 R241R, IL-8 -251AA/ IL-6 -174GG, IL-8 -
251AA/ PPAR-γ 34CC, TNF-α -308AA/ ICAM-1 R241R, TNF-α -308 GA/ IL-6 -
174GG and TNF-α -308AA/IL-6 -174GG emerged as high risk predisposition 
combination genotypes. From the results, it is presumed that the SNPs showing 
higher risk might be promoting CRC susceptibility by altering the properties of 
cytokines and chemokines and acting as negative regulators of cellular growth. It is 
reasonable to conclude that in a continuous inflammatory condition, genetic variation 
(SNPs) in immune and inflammation response genes, resulting in aberrant response 
of host’s immune system, could act as genetic predisposition factors, favouring 
inflammation mediated colorectal carcinogenesis. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1  Cancer-an overview 
  
Cancer is a disease or group of diseases, in which there is a diminution in control 
over cell proliferation and cell death in the affected tissues. Cancer is one in eight 
diseases that cause deaths worldwide (Garcia M, 2007). Cancer arises as a result of 
accumulations of multiple genetic alterations within cells. The accumulations of 
genetic abnormalities lead to the process of tumorigenesis and tumor progression. 
Abnormal proliferation, clonal expansion, invasion to the surrounding tissues and 
metastasis to distance sites occur after these genetic alterations. Tumorigenesis 
consists of several steps such as transformation of normal cells into neoplastic cells, 
resistance to apoptosis, autonomous growth signaling, existence of vascular supply, 
evasion of immunologic surveillance and also acquisition of invasive/metastasis 
properties (Brat et al., 2005). During tumorigenesis, genetic evolution occur which is 
also influenced by environmental factors. For example, environmental carcinogen 
exposure such as tobacco smoke can cause mutation in tumor promoting gene such 
as the K-Ras oncogene or inactivation of tumor suppressor gene and subsequently 
will lead to cancer development. Other factors that can influence cancer development 
are long term exposure to carcinogenic agents such as asbestos or ultraviolet rays. 
Environmental carcinogen that can lead to cancer development also can be due to 
prolonged to exposure infectious agents such as viruses. Exogenous mutagenic 
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exposures such as tobacco smoke carcinogens, chemicals like aflatoxins, fungi or 
radiation including ultraviolet will increase the rate of mutation in cells and will 
result in conversion of normal cells into cancer cells (Stephens et al., 2009).  
 
As a result of all these exposures, many genetic and epigenetic changes in cells, 
surrounding stroma and blood vessels will occur. These genetic alterations disrupt 
many molecular pathways in the cell which help the cell to acquire several 
mechanisms such as self-sufficiency in growth signals, insensitivity to growth 
control signals, evasion of apoptosis, limitless replicative potential, sustained 
angiogenesis, invasion and metastasis all of which can lead to development of cancer 
(Hanahan and Weinberg, 2000). Epigenetic changes which can cause alteration in 
chromatin structure and gene expression and change the methylation status of some 
cytosine residues at DNA sequence level (Stephens et al., 2009) also contribute to 
carcinogenesis. 
 
Cancer can be broadly classified into hereditary cancer and sporadic cancer. 
Hereditary cancers occur due to germline mutations at tumor suppressor or proto-
oncogenes, which may be inherited from one generation to another generation. 
Sporadic cancers occur due to the acquired mutations in a somatic cell and are not 
transmitted from one generation to another. The incidence of sporadic cancer is 
higher compared to hereditary cancer because it arises as a result of accumulation of 
multiple somatic mutations that occur spontaneously by environmental exposures. 
Cancer may affect any individual or human organ. Earlier studies on populations’ 
ecology and migration suggested that, risks of cancer development are largely 
influenced by environmental factors and also other lifestyle habits such as smoking 
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and food consumptions (Parkin and Muir, 1992). Later, researchers identified that 
heritable predisposition factors are also associated with various types of cancers 
including sporadic cancers (Knudson, 2002). Studies on genetic risk of cancer have 
reported that most sporadic cancers develop in genetically predisposed individuals. 
This predisposition usually involves genetic variation in several low penetrance 
genes rather than single gene mutations (Houlston and Peto, 2004, Imyanitov et al., 
2004). 
 
1.1.1 Cancer classification 
  
Cancer can be divided into several categories according its forms: 
1) Carcinoma- One type of cancer that occur in epithelial surface. It usually 
appears in the cells that form the outer surface of the body to line or cover the 
body’s cavities, tubes and passageways. 
2) Adenocarcinoma- Types of cancer that occur in form of grandular surface and 
usually occur in most types of cancer such as in lung cancer, breast cancer, 
prostate cancer, ovary or kidney. 
3) Sarcomas- Usually occur in supporting structures such as bone, cartilage, 
muscle, fat or fibrous tissues.  
4) Leukemias- Leukemia is a cancer of the bone marrow, the spongy center of 
the bones that makes blood cells. 
5) Lymphomas- Lymphomas are malignant cell infiltrations of the lymphatic 
system. The lymph system includes the nodes located in the neck, armpit, and 
groin. These nodes are only part of the lymph system, as they are connected 
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to each other and to the spleen, thymus, and parts of the tonsils, stomach, and 
small intestine by a network of vessels. 
Carcinoma and adenocarcinoma are the cancer types that frequently occur in humans  
rather than other types of cancers worldwide. 
 
1.1.2 Cancer diagnosis and staging 
 
As part of diagnosis of cancer, initially a complete history (family history, 
environmental exposure or prior illness) and physical examination (fatigue, weight 
loss, fevers or sweats, change in bowel habits or persistent pain) are important 
especially for the early diagnosis propose. The objectives of early diagnosis of cancer 
are to decrease cancer mortality, allow use of less radical therapy as well as reduce 
financial costs. Histopathological confirmation is one of  the processes for accurate 
cancer diagnosis. In short, for histopathology diagnosis, tissues or malignant cells are 
taken by inspiration, biopsy or surgery and examined under microscope after proper 
histopathological staining. In term of clinical practice, histopatology refer to 
examination of biopsy or surgical specimen to integral the cancer management 
through staging and grading of tumours. 
 
Recently, molecular diagnostics and imaging techniques also are being used for 
diagnosis of cancer. After a diagnosis is made, the next step is staging of cancer. 
Staging is determination of the extent of disease done after histologic diagnosis is 
made in order to determine treatment decision and prognosis. For clinical staging, 
clinician use patient history, physical examination and noninvasive studies. In case of 
pathology staging, specimen from malignant tissues is needed. Cancer staging 
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describes the extent or severity of individual’s cancer. Cancer staging is done based 
on the stage of cancer progression. Cancer staging consider the size of tumor, tumor 
penetration, cancer invasion, number of lymph nodes involved and also metastasis. 
The system commonly used for cancer staging is TNM system. For cancer staging, 
TNM system is based on extent of the tumor (T), number of nodes involved in cancer 
progression (N), and the presence of the distant metastasis (M). The number usually 
used for this system usually indicate the size (T), number of involvement of regional 
lymph nodes (N) as well as presence of metastasis (M).  
 
1.1.3 Cancer treatment 
 
Successful treatment of cancer is important in order to eliminate all cancer cells, 
whether at the primary site or metastatic areas of other regions of the body. There are 
three major types of cancer treatment that is familiar in clinical practice-Surgery, 
radiation therapy and chemotherapy. The functions of surgery and radiotherapy 
treatments are for local and local-regional diseases whereas chemotherapy is used for 
systemic sites.  
 
1.1.3.1 Surgery 
 
Surgery is the oldest mode of treatment and is applicable to tumors which are 
localized, and which can be resected. Surgery is suitable to various types of cancers 
such as cancer of the bladder, breast, cervix, colon, and other types of carcinomas 
and adenocarcinomas. If surgery cannot be performed, then the patients will be 
treated with other types of treatment such as radiotherapy and chemotherapy. 
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1.1.3.2 Radiotherapy 
 
Radiotherapy is the cancer treatment employing ionizing radiation, and can be 
delivered by various methods such as gamma radiation, neutron beam, electron beam 
and proton therapy. Radiotherapy requires local or local-regional disease that can be 
encompassed within the radiation field. In this treatment, radiation affects cells in 
random and nonspecific with complex effects on DNA. The efficacy of this treatment 
is influenced by cellular injury beyond the normal capacity of DNA repair and this 
allows differential cell kill. 
 
1.1.3.3 Chemotherapy 
 
Chemotherapy is the treatment in which chemotherapeutic drugs are targeted to 
cancer cell and directly destroy the cancer cells with minimal adverse effects or 
toxicities on normal cells. In chemotherapy treatment, multidrug regimens with 
differing mechanisms, intracellular sites of actions and toxicities provide significant 
cure rates to various types of human cancers. 
 
1.1.4 Cancer prevention 
 
Cancer prevention is an important way to fight against cancer. It is considered as 
activities to prevent other chronic diseases especially those with cancer related 
diseases. There is the need to monitor the trends of cancer risk factors in a population 
such as tobacco use, alcohol use, dietary factors including low fruit and vegetable 
intake, physical inactivity as well as overweight and obesity which are important for 
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predicting the future cancer risk and will be rational in decision making for cancer 
prevention.  
 
Other than that, a comprehensive surveillance and evaluation system also could be 
included in this cancer prevention policies and programmes. So, every country has 
undertaken primary cancer prevention in order to prevent unnecessary suffering and 
premature death.  
 
1.2 COLORECTAL CANCER 
 
In humans, colon and rectum are segments of the large intestine, as parts of the 
digestive system. Colon makes up the first 6 feet of the large intestine and the rectum 
makes up the last 8 to 10 inches ending near the anus. Colon and rectum play 
important roles in the body’s ability to digest food and excrete waste. Colorectal 
cancer (CRC) is the cancer commonly arising in the epithelium of the colon and 
rectum. CRC is second leading cause of cancer deaths and according to latest reports, 
approximately 5 % of world population are developing this cancer (Bunz, 2008). 
CRC commonly appear in form of adenocarcinoma histological type in epithelial 
cells. In the early development of CRC, a growth of cells that often extend into 
bowel wall and into lumen intestinal, called polyps, appear. Polyps can be divided 
into two histological classes’ non-dysplastic and dysplastic (adenomatous) polyps. 
The dysplastic polyps are ordered epithelial structures which are similar to normal 
crypts. These epithelial cells line up in multiple layers and enhance increasing rate of 
enlargement of nuclei within the cells. Slowly, the adenomas become larger in size 
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and are more likely to invade to the surrounding tissues, at which point they are 
defined as malignant (Bunz, 2008). 
 
CRC occur commonly as sporadic form and a less commonly as hereditary form. 
Hereditary CRC make up ~8% to 15% of all cases of CRC whereas sporadic CRC 
accounts for nearly 80% to 85% of cases. Familial Adenomatous Polyposis (FAP) 
and Hereditary non-polyposis Colorectal Cancer (HNPCC) are 2 major forms of 
hereditary CRC. FAP arises from genetic mutations in the adenomatous polyposis 
coli (APC) gene. HNPCC is caused by genetic mutation in the family of mismatch 
repair gene (MMR), which include MLH1, MSH2, MSH6 and PMS2 (Plotz et al., 
2006, Dionigi et al., 2007, Lagerstedt Robinson et al., 2007). Germline mutations in 
1 of these 4 MMR genes have been identified in 80% of HNPCC affected families. 
Among the germline mutations, almost 50 % are affecting the MLH1, 40% affecting 
MSH2 and the rest 10% are involving the MSH6 and PMS2 genes. The MMR system 
functions to preserve genomic integrity and hence, defects in this DNA repair 
function lead to the development of HNPCC and few other solid tumors included in 
the Lynch Syndrome.  
 
1.2.1 Genetic alterations in CRC 
 
The development of CRC progresses through a series of clinical and 
histopathological changes, starting with single crypt lesion in small benign tumor 
(adenomatous) and develops to cancer cells (carcinomas) (Migliore et al., 2011). The 
progression of CRC is a multistep process involving several alterations in tumor 
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suppressor genes as well as oncogenes. These various genetic alterations and changes 
that may influence the initiation and progression of cancer could be explained by the 
colorectal tumorigenesis model (Fearon and Vogelstein, 1990). Etiologically, 
sporadic colorectal cancer (CRC) is a complex and multifactorial disease that is 
linked to both exogenic and endogenic factors.  
 
CRC is multi-factorial disease, which can be influenced by several factors such as 
ethnicity, gender and geography. A study by Read et al (2006)) had showed that, the 
African-American males over 50 years in Western population were at higher 
predisposition risk for CRC. 
 
Sporadic colorectal carcinogenesis is a multistep process which involve stepwise 
accumulation of multiple genetic and epigenetic alterations in tumor suppressor 
genes, oncogenes and DNA mismatch repair genes which results in the 
transformation of normal to malignant cells (Tahara, 2007). The formation of a 
malignant tumour through adenoma from normal cells has been reported to involve 
inactivation of genes such as APC, p53 and DCC as well as K-ras mutations which is 
also a major genetic pathway for colorectal carcinogenesis. Researchers have 
reported that, loss of heterozygosity and mutation of APC genes occur in about 60% 
of sporadic CRC adenoma and adenocarcinomas (Tahara, 2007). Approximately 10-
20 genetic events are estimated to occur in the interval between initiation and 
presentation of frank colorectal carcinoma. For early diagnosis and also to reduce the 
morbidity and mortality, it is reasonable to understand the genes as well as pathways 
that cause the CRC development. Most sporadic CRC which is almost 85% have 
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chromosomal instability usually allelic imbalance at chromosomal loci and 
chromosomal amplification and translocation that both can contribute to tumor 
aneuploidy (Lothe et al., 1993).  Another 15% have high frequencies of 
microsattelite instability phenotypes like frame-shift mutation and substitution and 
most frequently is short tandem repeated nucleotide sequences known as 
microsatellite (Ionov et al., 1993). About 80% of sporadic CRC occur when somatic 
mutations occur in APC which suggest sporadic colorectal tumorigenesis is similar to 
FAP adenoma to carcinoma sequence (Bienz and Clevers, 2000). 
 
1.2.2 Incidence of CRC 
 
Colorectal cancer (CRC) represents a significant cause of morbidity and mortality 
worldwide. The latest data show that, more than one million CRC patients are 
diagnosed in developed countries every year, and the rate of mortality from that 
value is almost 33% (Cunningham et al., 2010). Even though earlier, CRC was 
reported to be commonly occuring in western countries, the incidence of CRC has 
been reported to be increasing in Asian countries including China, India, Indonesia, 
Japan, South Korea, Malaysia, Philippines, Singapore, Taiwan and Thailand in the 
last few decades. In general, the incidence of CRC has been increasing worldwide 
including Malaysia during the past few years. In Japan, incidence of CRC was 
reported to be higher compared to gastric cancer (Yiu et al., 2004). The incidence of 
CRC was reported to be increased by the time, become the second commonest cancer 
(Tamura et al., 1996) and the mortality of CRC also has been reported to be doubled 
in both men and women over past few decades in Singapore (Chen et al., 2002). In 
Asian countries, there are many different ethnic groups and it has been observed that 
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the incidence of CRC varies among different ethnic groups. In Malaysia, there are 
three major ethnic groups which are Malay, Indian and Chinese. It has been reported 
that, Chinese people showed significantly higher incidence of CRC than Malays and 
Indians (Lim et al., e2002). 
  
In developed countries such as Netherlands, USA and Germany, CRC has been 
reported to be one of major causes of cancer deaths. In Netherlands, 9500 new cases 
were diagnosed with CRC in 2002 (Siezen et al., 2006), in USA about 147 500 new 
cases of CRC and 57 100 deaths were caused by CRC in 2003 (Gong et al., 2005). 
For CRC cases in Germany, more than 71 000 new cases were diagnosed and the 
incidence and mortality of CRC in Germany is almost highest all over the world 
(Sieg and Friedrich, 2009). According to National Cancer Registry report, in 
Malaysian population, CRC is considered as second most common cancer after 
breast cancer (Figure 1.1) and showed the leading cancer among males (Figure 1.2) 
in Peninsular Malaysia. However, only 13.2 % of CRC cases were registered with 
National Cancer Research which included 2,866 cases (Omar et al., 2006). 
 
1.2.3 Risk factors for CRC 
 
CRC usually arise sporadically in most of the cases. There are several factors that 
contribute to cancer development. The risk factors that influence CRC development 
include increasing age, male sex, previous colonic polyps or previous CRC, and 
environmental factors. So the environmental factors that enhance colorectal cancer 
development are red meat consumption, high-fat diet, inadequate intake of fibre in 
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diet, obesity, diabetes mellitus, smoking, high alcohol consumption and lack of 
physical activity. 
 
Epidemiologic studies of Western populations have emphasized the large 
contribution of food and lifestyle on sporadic CRC risk (Kushi and Giovannucci, 
2002, Slattery et al., 2003, Heavey et al., 2004). High fat and low fiber diets, as well 
as alcohol, tobacco and red or processed meat consumption, have been shown to 
produce high level of polycyclic aromatic amines. These pro-carcinogenic agents are 
potentially very harmful and may play a key role in malignant transformation by 
interacting with DNA (Berlau et al., 2004, Potter, 1996). Study on Japanese 
population showed that, dietary habits such as consumption of red meat and animal 
fat were associated with increased risk of incidence of CRC (Yiu et al., 2004). A 
similar study in Shanghai showed that consumption of red meat, and also preserved 
food caused increase in the number of CRC in China (Chiu et al., 2003).  
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Figure 1.1: Ten most frequent cancers, Peninsular Malaysia 2006 
Adapted from (Omar et al., 2006). 
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Figure 1.2: Ten most frequent cancers in males, Peninsular Malaysia 2006 
Adapted from (Omar et al., 2006). 
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It has been well documented that chronic inflammation is also a risk factor for CRC 
development. This has been illustrated by the increased incidence of CRC in patients 
with inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative 
colitis (von Roon et al., 2007). The risk of inflammation to CRC development 
influence by duration of the illness because researchers reported inflammatory 
associated-CRC diseases increase risk for CRC development 2 % at 10 years and 
18% by 30 years (Eaden et al., 2001), severity and extent inflammation (Itzkowitz 
and Harpaz, 2004).  
 
1.3 Inflammation and Colorectal cancer 
  
Inflammation is a physiologic process caused by microbial pathogen infection, 
chemical irritation and/or wounding. Inflammation has been reported to be involved 
in the development of several cancers such as stomach, lung, colon and prostate 
(Babbar and Casero, 2006). Chronic inflammation and carcinogen exposures are 
considered as important factors in cancer development (Coussens and Werb, 2002). 
There are several factors that enhance chronic inflammation leading to cancer 
development including microbial infection, autoimmune diseases and inflammatory 
condition that have unknown origin. Inflammation play important roles in cancer 
development by activation and induction of several oxidant-generating enzymes 
NADPH oxidase and inducible nitric oxide synthase (iNOS) which can lead to DNA 
damage as well as tumour development.  
 
Several lines of evidence including animal models and epidemiological observations 
suggest that a continuous inflammatory condition predisposes to various types of 
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cancers including CRC. Patients with inflammatory bowel disease (IBD), including 
Crohn disease (CD) and ulcerative colitis (UC), are at increased risk of developing 
colorectal cancer (Munkholm, 2003). Researchers had suggested that site of chronic 
inflammation in IBD influence the risk of CRC. For example the infection site found 
in colon will increase risk of CRC predisposition (Feagins et al., 2009). Another 
study found an association between inflammatory response genes and IBD. This 
study also showed increased risk of CRC susceptibility for those with IBD and they 
reported that approximately 1 out of 6 individuals with IBD developed CRC 
(Lakatos et al., 2007).   
 
In a continuous inflammatory environment, tumours enhance the cell basement 
membrane breakage which is needed in the invasion and migration processes of the 
tumor cells (Coussens and Werb, 2002). Researchers have found macrophages, 
eosinophils, dendritic cells, mast cells and lymphocytes, as the components that 
cause epithelial-originated tumors (Coussens and Werb, 2001, Macarthur et al., 
2004, Yang et al., 2005). During chronic inflammation, free radicals and aldehydes 
are produced which can enhance modification of post-translational and gene 
mutation of cancer-related protein (Hussain et al., 2003). Cytokines and chemokines 
released by inflammatory mast cells were found to enhance the tumor progression 
(Lin and Pollard, 2004).  Chronic inflammation such as Barret esophagus and 
chronic gastritis that occur at gastrointestinal tract has been reported to lead to the 
cancer cell development (Genta, 2003, McKay et al., 2008, Zhang et al., 2009).  
 
Studies on genomic instability of CRC had shown that, genetic mutation was linked 
to oxidative damage from chronic inflammation (Atreya and Neurath, 2008, Xie and 
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Itzkowitz, 2008). Individuals with intestinal inflammation such as ulcerative  colitis 
and Crohn’s disease showed increased risk of CRC predisposition especially at early 
age (<30 years old) (Children's Oncology Group. and SEER Program (National 
Cancer Institute (U.S.)), 2006). Researchers have reported that, the predisposition 
risk of CRC was increased by 10-fold when it was linked with ulcerative colitis and 
Crohn’s disease (Seril et al., 2003, Itzkowitz and Yio, 2004). 
 
1.3.1 Genetic predisposition 
 
Having a genetic predisposition for a disease does not mean that individual will 
develop the disease, but that individual’s risk may be higher than that of the general 
population. The etiology of CRC is complex and likely involves multiple low 
penetrance susceptibility genes, the influence of environmental exposures such as 
cigarette smoke, carcinogens in diet, air pollution and the interaction of genotype and 
environments. There are several levels that expose to CRC development. At the 
cellular level, the epithelial cell gets exposed to a range of toxic and also pathogenic 
factors including imbalance of intestinal microflora. Researchers have found that, 
microflora can cause changes of immune response as well as induction of 
inflammation in gut (Macdonald and Monteleone, 2005). So, chronic inflammation is 
documentated as an underlying cause in the development of many gastronintestinal 
malignancies including CRC. From earlier studies, researchers suggested that almost 
35% of sporadic CRC are attributed to genetic susceptibity (Lichtenstein et al., 
2000). So genetic susceptibility of the host on interacting with environmental factor 
can contribute to sporadic CRC development.  
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1.4 Present study-importance. 
 
The increasing incidence of CRC and its associated mortality and morbidity are 
demanding much research with regard to its aetiology, diagnosis and treatment. Early 
detection can significantly help in better treatment outcomes for CRC. Current 
screening methods are based on colonoscopies and faecal occult blood testing. Even 
though faecal occult blood testing is simple, relatively cheap and non invasive, the 
problem of low specificity and inability in differentiating between upper and lower 
gastrointestinal bleeding, is a limitation. Colonoscopy, despite its effectiveness, is 
usually less likely undertaken by patients and are also associated with higher costs 
and risk. Therefore, there is the need to identify novel biomarkers to detect early 
occurrence of colorectal malignancy. 
 
Identifying predisposing genetic variations is important for our understanding of the 
carcinogenic process. Chronic inflammation is a common underlying cause in the 
development of many gastrointestinal cancers including CRC and is considered as a 
predisposing factor for malignant transformation. Despite several evidences strongly 
implicating chronic inflammation as a culprit in colorectal carcinogenesis, 
surprisingly little research has directly addressed the genetic predisposing factors 
which mediate inflammatory response and favors CRC development. Genetic 
polymorphisms (single nucleotide polymorphisms) have emerged in recent years as 
important determinants of disease susceptibility and severity. A great deal of 
attention has been focused on the field of genetic polymorphisms in the host as 
factors contributing to cancer predisposition. Genetic polymorphism is a single base 
change thought to occur in every 500 – 1000 nucleotides and maybe present in more 
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than 1% of the population. Polymorphic variants of several genes are thought to play 
a key role in determining how individuals respond at the cellular level to various 
environmental conditions including inflammation. The propensity to mount an 
inflammatory response could be modified by germline variation in cytokine and 
other inflammation related genes. In the magnitude of an inflammatory response, 
genetic polymorphisms directly influence inter-individual variation which clearly 
contributes to the ultimate clinical outcome of an individual (Hold and El-Omar, 
2008).  
 
The associations between polymorphisms in inflammatory response genes and IBD 
make them attractive candidate susceptibility genes for colorectal cancer since 
approximately 1 in 6 individuals with IBD will develop malignancy (Lakatos et al., 
2007). Despite these evidences strongly implicating chronic inflammation as a culprit 
in colorectal carcinogenesis, surprisingly little research has directly addressed the 
genetic predisposing factors which mediate inflammatory response and favors CRC 
development. If inflammation constitutes one of the molecular networks 
underlying susceptibility to CRC, genes which mediate inflammatory response 
might be a group of candidate genes for CRC predisposition. So it was of 
interest to explore the contribution of SNPs in inflammation genes as 
predisposing factors for CRC susceptibility. 
 
Few genes such as interleukin 6 (IL-6), interleukin 8 (IL-8), tumour necrosis factor 
alpha (TNF-α), intercellular adhesion molecule 1(ICAM-1) and also peroxisome 
proliferator-activated receptor gamma (PPAR-γ) are known to be important for 
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inflammation of colorectum and their allelic variants have been shown to have 
biological effects. 
 
Interleukin-6 (IL-6) is a pro-inflammatory cytokine and is known to ameliorate p53 
function which favours cell survival and also induce other anti-apoptotic genes. In 
humans, IL-6 SNP -174 G>C (rs1800795) in the promoter region has been reported 
to increase IL-6 levels (Bonafe et al., 2001). 
 
Tumor necrosis factor- alpha (TNF-α) is a powerful pro-inflammatory cytokine that 
is produced in the gastric mucosa in response to H.pylori infection. The TNF-α -308 
G>A (rs1800629) polymorphism is known to be involved in a number of 
inflammatory conditions.  
 
Interleukin-8 (IL-8) is another important cytokine belonging to CXC family. It has 
effects on cell proliferation, migration and tumor angiogenesis. IL-8 has a well 
established promoter polymorphism at position -251 T>A (rs4073). 
 
Peroxisome proliferator activated receptor gamma (PPAR-γ) gene is usually found 
to be expressed in macrophages, and influences the production of inflammatory 
cytokine as well as aided the regulation in the inflammatory responses. There are 
four isoforms of the PPAR-γ gene that differ by their transcriptional start site and 
splicing. SNPs in PPAR- γ that is frequently found to be associated with the gene 
expression is a proline to alanine (Pro12Ala) (rs1801282) substitution in exon B.  
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Intercellular adhesion molecule 1 (ICAM-1) play important roles in the migration 
of neutrophils to inflammatory sites and also involve in various types inflammatory 
diseases. There are two SNPs in ICAM-1 genes which are commonly implicated in 
the susceptibility to several inflammatory diseases which are K469E (rs5498) and 
R241G (rs1799969). 
 
There is not much data available on the contribution of SNPs in inflammation 
response genes in mediating CRC predisposition risk, especially from Asian 
population and none from Malaysian population. So this study was designed to 
investigate the association of genetic variation of inflammation response genes with 
CRC susceptibility risk in Malaysian population.  
 
It was hypothesized that genetic variations (SNPs) in inflammation response genes 
would be associated with colorectal carcinomas. In order to test this genetic 
association, a case control study was designed with the following objectives. 
 
1.5 Objectives of the Research 
 
The main objective was to investigate the influence of genetic polymorphisms of few 
inflammation response genes (genes which are known to be important for 
inflammation of the colorectum) on CRC susceptibility risk in Malaysian population. 
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1.5.1 Specific Objectives 
 
1 To genotype the sporadic CRC patients and normal controls for the 
inflammation response gene SNPs IL-6-174 G>C, IL-8-251 T>A, TNF-α -308 
G>A, ICAM-1 K469E, ICAM-1 R241G, and PPAR-γ 34 C>G. 
2 To determine the polymorphic genotype and allele frequencies of 
inflammation response genes such as IL-6-174 G>C, IL-8-251 T>A, TNF-α -
308 G>A, ICAM-1 K469E, ICAM-1 R241G, and PPAR-γ 34 C>G in the 
healthy normal Controls and Sporadic Colorectal Cancer patients in 
Malaysia. 
3 To investigate the associated risk of polymorphic genotype and allele of these 
genes, either as single variant and / or combination of variants, with CRC 
susceptibility. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 Relationship between inflammation and cancer 
 
Sporadic colorectal cancer is a multi-factorial caused disease, arising as a result of 
interaction between environmental factors and genetic predisposition. Several lines 
of evidence including animal models and epidemiological observations had 
suggested that a continuous inflammatory condition could predispose to various 
types of cancers including colorectal cancer. During the last decade, a great deal of 
attention has been focused on the relationship between chronic inflammation and 
cancer. A link between inflammation and cancer was already observed in nineteenth 
century by Rudolf Virchow, when he found that tumor cells were present at site of 
chronic inflammation and the inflammatory cells were found among the tumor cells 
(Balkwill and Mantovani, 2001). At that time, he suggested that, the site of chronic 
inflammation had ‘lymphoreticular infiltrate” which reflected to origin of cancer. 
Accumulating data had supported that tumor cells were originated at chronic 
inflammation sites (Mueller and Fusenig, 2004). Many of the inflammatory 
responses had been reported to lead to various types of cancer even though 
inflammation act as adaptive host defense against infection or injury (Jackson and 
Evers, 2006, Schottenfeld and Beebe-Dimmer, 2006). Researchers observed that, 
almost 25 % of cancers originated from chronic inflammation (Hussain and Harris, 
2007).  
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2.2 Role of inflammation in CRC development. 
 
The pathogenesis of colorectal cancer is multi-factorial and complex. Since most 
CRC arise sporadically, environmental and host immunological factors has been 
reported to significantly contribute to the initiation and progression of this 
malignancy (Landi et al., 2003). Chronic inflammation can often predispose to 
malignant transformation. When injury or inflammation occurs, various 
inflammatory cells are recruited to the site of that particular area. The mechanism of 
inflammation start with macrophages and mast cells that are prestationed at tissues, 
which enhances the migration of neutrophil to the inflammation site, and then the 
inflammatory cells with various types of leukocytes and lymphocytes signal the 
production of growth factors, cytokines and chemokines (Coussens and Werb, 2002, 
Nathan, 2002). After that, cells recruited at the inflammation sites strengthen and 
maintain defense against infection processes (Coussens and Werb, 2002). Then, 
acute inflammation enhances the production of cytokines and chemokines to attract 
the immune and non-immune cells to infiltrate the inflammation areas.  The 
production of proinflammatory cytokines gives way to anti-inflammatory and healing 
process which usually occurs in acute inflammation and is a self-limiting process 
(Fadok et al., 1998, Hodge-Dufour et al., 1998).  
 
Immune response has a significant impact on the potential for malignancy, which has 
been highlighted by the clear association between chronic inflammatory conditions 
and subsequent malignant transformation in the inflamed tissues. According to 
Theodoropoulus et al., (2006) inflammation favours tumorigenesis by stimulating 
angiogenesis, damaging DNA and chronically stimulating DNA proliferation. In a 
